No registrations found.
ID
Source
Brief title
Health condition
cannabis
psychosis
dopamine
Sponsors and support
Intervention
Outcome measures
Primary outcome
A. Striatal dopamine response after THC and placebo, as measured with PET and [18F]fallypride
B. Psychotic experiences after THC and placebo, as measured with i) novel computer-assisted tasks and ii)clinical interviews
Secondary outcome
C. Influence of genetic variation
Background summary
The study aims at elucidating the biological mechanism behind the cannabis-psychosis relationship. By using PET and [18F]fallypride, the striatal dopamine response is measured after THC or placebo exposure. Novel computer-assisted tasks as well as clinical interviewing are used to assess psychotic experiences behaviorally.
Study objective
1. Cannabis use increases striatal dopamine release
2. Striatal dopamine release predicts cannabis induced-psychotic experiences
3. Cannabis-induced striatal dopamine response varies as a function of genetic risk for psychosis
Study design
One timepoint (t1)
Intervention
Exposure to delta-9-tetrahydrocannabinol (THC, psychoactive component of cannabis, 8 mg) and placebo
Dept. Psychiatry and Neuropsychology
PO Box 616 (loc. Vijverdal)
Rebecca Kuepper
Maastricht 6200 MD
The Netherlands
+31 (0)43 3688658
r.kuepper@sp.unimaas.nl
Dept. Psychiatry and Neuropsychology
PO Box 616 (loc. Vijverdal)
Rebecca Kuepper
Maastricht 6200 MD
The Netherlands
+31 (0)43 3688658
r.kuepper@sp.unimaas.nl
Inclusion criteria
1. Aged between 18 and 50
2. Life-time use of cannabis without having experienced negative effects (e.g. bad trip, toxic psychosis)
3. BMI between 18.5 and 27
4. Having signed informed consent
5. Clinical diagnosis of non-affective schizophrenia or psychotic disorder according to DSM-IV
(REFERS ONLY TO PATIENTS)
Exclusion criteria
1. Head trauma
2. Respiratory, cardiovascular, neurological disease, severe renal or liver dysfunction
3. Alcohol use in excess of 5 units per day
4. Weekly use of illicit drugs (other than cannabis)
5. Current use of antipsychotic medication or medication known to interfere with the CB1 receptor (e.g. rimonabant)
6. Pregnancy and breastfeeding
7. Personal or family history of psychosis
(REFERS ONLY TO HEALTHY CONTROLS)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1272 |
| NTR-old | NTR1318 |
| Other | : 200801 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |